The targeting of tumor-associated macrophages by vaccination

Affiliations:

¹ National Center for Cancer Immune Therapy (CCIT-dk), Copenhagen University Hospital, Herlev, DK-2730 Herlev, Denmark.

² Department of Immunology and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark.

³ IO Biotech ApS, DK-2200 Copenhagen, Denmark.

Keywords: 

anti-Tregs, immune modulatory vaccines, IDO, arginase, PD-L1, CCL22, T-win.

Abbreviations:

IDO – indoleamine 2,3-dioxygenase,

NSCLC – non-small-cell lung carcinoma,

TAM – tumor-associated macrophage,

TME – tumor microenvironment,

Treg – regulatory T-cell.

Corresponding Author(s):

Conflict of interest statement:

MHA has filed several patent applications based on the use of CCL2, CCL22, PD-L1, PD-L2, arginase, TDO, or IDO for vaccinations. The rights of the patent applications have been transferred to Copenhagen University Hospi-tal, Herlev, according to the Danish Law of Public Inven-tions at Public Research Institutions. The capital region has licensed some of these patents to the company IO Biotech ApS, whose purpose is to develop immune modulating vaccines for cancer treatments. MHA is a shareholder and board member of IO Biotech ApS.

Please cite this article as:

Mads Hald Andersen (2019). The targeting of tumor-associated macrophages by vaccination. Cell Stress 3(5): 139-140. doi: 10.15698/cst2019.05.185

© 2019 Andersen. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.